News and Trends 2 Sep 2022 Cancer drug for children and young people with glioblastoma given to patients in study Clinical-stage bio company, Onxeo, has announced that the first patients have been enrolled and treated in a phase 1b/2 clinical study. The study is to evaluate the efficacy and tolerability of AsiDNA2, a DDR inhibitor combined with radiotherapy in children, adolescents or young adults with relapsed high grade glioma (HGG). Onxeo, which focuses on drugs […] September 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Study of injection to treat schizophrenia to begin after $3M payment received A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision to start the trial for mdc-TJK this week (August 29). Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia can produce a […] September 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Gel treatment for erectile dysfunction receives positive results from clinical trial Futura Medical has announced positive results from a clinical trial looking into MED3000, a topical gel formulation for the treatment of erectile dysfunction (ED). The results, from the confirmatory phase 3 clinical study, FM71, were announced today (August 31). MED3000 is a breakthrough, fast-acting gel produced by Futura Medical’s transdermal DermaSys drug delivery technology. It […] August 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Regulatory approval given to Iceland’s EpiEndo for study of COPD treatment A treatment for chronic respiratory disorders will be the subject of a clinical trial in Iceland after regulatory and ethics approval was granted. EpiEndo Pharmaceuticals will start a clinical trial of its lipopolysaccharide challenge with lead molecule EP395. Available orally, EP395 is an macrolide or Barriolide with reduced antimicrobial activity which aims to address the […] August 31, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 United BioPharma gets FDA approval for phase 2 HIV drug trial Taiwan-headquartered United BioPharma (UBP) says the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of the study is to assess the safety and antiviral activity of UB-421 in combination with optimized background ART […] August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Emactuzumab designated as an orphan medicinal product for TGCT in Europe SynOx Therapeutics Limited says its novel monoclonal antibody, emactuzumab, in development for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been designated as an orphan medicinal product for both localized and diffuse types of the disease by the European Medicines Agency (EMA). No systemic treatments have been approved for TGCT in […] August 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer Patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases have completed their last visit in a clinical trial studying the drug, Zorifertinib. Drugs developer, Alpha Biopharma, announced the completion today (August 25) of last patient last visit (LPLV) in its international, multicenter EVEREST phase 2/3 study of the next-generation […] August 25, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Clearance given to clinical trial with potential to change course of brain disease A trial to look at gene therapy, BV-01, for Huntington’s Disease has been given the go ahead to take place in France and has ‘the potential to change the course of the devastating disease. Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, received clearance for the phase 1/2 […] August 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Oncolyze seeking investment for AML clinical trials After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, […] August 24, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 180 Life Sciences announce enrollment of the first patient in frozen shoulder treatment trial The first patient has been enrolled on a clinical trial to evaluate anti-tumor necrosis factor for patients with early-stage, pain predominant frozen shoulder. 180 Life Sciences, a clinical-stage biotechnology company made the announcement yesterday (August 22). James Woody chief executive officer of 180 Life Sciences, said: “Recruiting the first patient for the trial of anti-TNF […] August 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Alume Biosciences progressing with fluorescence study in patients undergoing head and neck surgery Alume Biosciences, Inc. says the first patient has been dosed in a phase 3 pivotal study of ALM-488, a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery. “The successful initiation of this phase 3 pivotal study is another major milestone for Alume Biosciences. It marks the final phase of clinical […] August 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2022 Santhera and ReveraGen announce first patient with Becker muscular dystrophy dosed in FDA-funded pilot study The first patient has been dosed in a phase 2 pilot study looking at a treatment for muscular dystrophy. Santhera Pharmaceuticals and ReveraGen BioPharma made the announcement that vamorolone is to be assessed in patients with Becker muscular dystrophy (BMD). The study is being funded by the U.S. Food and Drug Administration (FDA). Eric Hoffman, […] August 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email